$ビリオス・セラピューティクス(VIRI.US)$Virios Therapeutics Announces Publication Of International Patent For IMC-2 Covering Antiviral Treatment Of Long-COVID Benzinga· 1 min ago
$ビリオス・セラピューティクス(VIRI.US)$Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent.
$ビリオス・セラピューティクス(VIRI.US)$Virios Therapeutics: Discussions Ongoing With Potential Partners to Fund Advancement of IMC-1 Into Phase 3 Development for FM >VIRI Dow Jones· just
$ビリオス・セラピューティクス(VIRI.US)$Moomoo 24/7· 1 min ago Virios Therapeutics To Advance Development Of IMC-2 As Treatment For Symptoms Associated With Long-COVID
$ビリオス・セラピューティクス(VIRI.US)$ November 2, 2023 Dear Virios (VIRI) Shareholders, We wanted to provide you with a succinct corporate progress report as we exit the third quarter of 2023, which can be summarized as follows: ● Having secured FDA guidance on our plan to progress IMC-1 to Phase 3 development to treat fibromyalgia, we can convey that several life science companies are engaged and reviewing our Phase 2 data and proposed Phase 3 program as the basis for a potential forward development p...
ビリオス・セラピューティクスに関するコメント
Update
Benzinga· 1 min ago
What’s the news?
Not bad!
Update! Watching
Dow Jones· just
Update
Virios Therapeutics To Advance Development Of IMC-2 As Treatment For Symptoms Associated With Long-COVID
Wen buyout?
we are bubbling here…
😍
November 2, 2023
Dear Virios (VIRI) Shareholders,
We wanted to provide you with a succinct corporate progress report as we exit the third quarter of 2023, which can be summarized as follows:
●
Having secured FDA guidance on our plan to progress IMC-1 to Phase 3 development to treat fibromyalgia, we can convey that several life science companies are engaged and reviewing our Phase 2 data and proposed Phase 3 program as the basis for a potential forward development p...
まだコメントはありません